GSA Capital Partners LLP Trims Stock Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

GSA Capital Partners LLP reduced its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 63.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 345,632 shares of the biopharmaceutical company’s stock after selling 587,544 shares during the quarter. GSA Capital Partners LLP owned about 0.17% of Sangamo Therapeutics worth $299,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Meritage Portfolio Management lifted its position in Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the period. Golden State Equity Partners increased its position in Sangamo Therapeutics by 35.2% during the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 69,368 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at $67,000. 56.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SGMO has been the topic of a number of analyst reports. StockNews.com upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 14th. Barclays upped their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, November 14th.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $1.88 on Friday. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a 50 day simple moving average of $1.43 and a two-hundred day simple moving average of $0.91. The firm has a market cap of $392.26 million, a P/E ratio of -2.51 and a beta of 1.10.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the prior year, the company earned ($0.34) EPS. On average, sell-side analysts anticipate that Sangamo Therapeutics, Inc. will post -0.52 earnings per share for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.